Previous Close | 0.4800 |
Open | 0.5840 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.5315 - 0.5840 |
52 Week Range | 0.4700 - 1.4100 |
Volume | |
Avg. Volume | 1,196 |
Market Cap | 6.655M |
Beta (5Y Monthly) | 1.31 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9640 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
MISSISSAUGA, Ontario, May 24, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Dale MacCandlish Weil to its Board of Directors (Board).
MISSISSAUGA, Ontario, May 16, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2022 Virtual Annual Meeting of Shareholders held on May 16, 2022 (the Meeting), all nominees listed in the management proxy circular dated April 8, 2022 were elected as directors of the Company.
MISSISSAUGA, Ontario, May 16, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2022. For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements f